Virus cocktail targets superbug lung infection in first human test
NCT ID NCT07429162
First seen Feb 28, 2026 · Last updated May 24, 2026 · Updated 10 times
Summary
This early-phase trial tests a special virus cocktail (phages) designed to attack a drug-resistant lung infection caused by Mycobacterium abscessus. One participant will receive the phage therapy alongside standard antibiotics. The goal is to see if the treatment can reduce bacteria in the lungs and improve breathing. This is a first step to see if the approach is safe and promising.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.